AngioDynamics Lifts Sales Outlook as 2Q Loss Narrows

Dow Jones

01/06

By Connor Hart

AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors.

The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share.

The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million.

The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier.

On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share.

Quarterly sales gained 8.8% to $79.4 million, topping Wall Street models for $76.4 million.

Sales of medical devices rose 5.6% to $43.8 million, while sales of medical technologies climbed 13% to $35.7 million..

Chief Executive Jim Clemmer said the company's strategic transformation is bearing fruit, as its medical technologies continue to gain share. He added the company will capitalize on momentum by continuing to invest across its medical technology portfolio.

Clemmer also said he intends to retire next year, prompting AngioDynamics' board to establish a new committee to conduct a search for the company's next CEO.

Shares rose 8.7%, to $14.38, in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 06, 2026 06:27 ET (11:27 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601899700"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601899700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601899700?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601899700","market":"sg","top_or_hot":-1,"title":"AngioDynamics Lifts Sales Outlook as 2Q Loss Narrows","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors. \n</p>\n<p>\n  The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share. \n</p>\n<p>\n  The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million. \n</p>\n<p>\n  The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier. \n</p>\n<p>\n  On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share. \n</p>\n<p>\n  Quarterly sales gained 8.8% to $79.4 million, topping Wall Street models for $76.4 million. \n</p>\n<p>\n  Sales of medical devices rose 5.6% to $43.8 million, while sales of medical technologies climbed 13% to $35.7 million.. \n</p>\n<p>\n  Chief Executive Jim Clemmer said the company's strategic transformation is bearing fruit, as its medical technologies continue to gain share. He added the company will capitalize on momentum by continuing to invest across its medical technology portfolio. \n</p>\n<p>\n  Clemmer also said he intends to retire next year, prompting AngioDynamics' board to establish a new committee to conduct a search for the company's next CEO. \n</p>\n<p>\n  Shares rose 8.7%, to $14.38, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:27 ET (11:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Lifts Sales Outlook as 2Q Loss Narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Lifts Sales Outlook as 2Q Loss Narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 19:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors. \n</p>\n<p>\n  The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share. \n</p>\n<p>\n  The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million. \n</p>\n<p>\n  The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier. \n</p>\n<p>\n  On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share. \n</p>\n<p>\n  Quarterly sales gained 8.8% to $79.4 million, topping Wall Street models for $76.4 million. \n</p>\n<p>\n  Sales of medical devices rose 5.6% to $43.8 million, while sales of medical technologies climbed 13% to $35.7 million.. \n</p>\n<p>\n  Chief Executive Jim Clemmer said the company's strategic transformation is bearing fruit, as its medical technologies continue to gain share. He added the company will capitalize on momentum by continuing to invest across its medical technology portfolio. \n</p>\n<p>\n  Clemmer also said he intends to retire next year, prompting AngioDynamics' board to establish a new committee to conduct a search for the company's next CEO. \n</p>\n<p>\n  Shares rose 8.7%, to $14.38, in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:27 ET (11:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANGO","symbol_name":"Angiodynamics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601899700","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601899700","pubTimestamp":1767698820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors.The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share.The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million.The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier.On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share.Clemmer also said he intends to retire next year, prompting AngioDynamics' boar","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANGO":"Angiodynamics"},"translate_title":"随着第二季度亏损收窄，AngioDynamics上调销售前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors. \n\n\n  The medical-technology company on Tuesday said it now expects sales of $312 million to $314 million for the year, up from a prior outlook of $308 million to $313 million. It backed its outlook for an adjusted loss of 33 cents to 23 cents a share. \n\n\n  The company noted that its forecast includes an up-to-$6 million impact from tariffs. Analysts polled by FactSet are looking for an adjusted loss of 33 cents a share on sales of $310.3 million. \n\n\n  The new sales outlook came as AngioDynamics narrowed its loss to $6.35 million, or 15 cents a share, for its quarter ended Nov. 30, from a loss of $10.7 million, or 26 cents a share, a year earlier. \n\n\n  On an adjusted per-share basis, AngioDynamics broke even. Analysts had expected an adjusted loss of 10 cents a share. \n\n\n  Quarterly sales gained 8.8% to $79.4 million, topping Wall Street models for $76.4 million. \n\n\n  Sales of medical devices rose 5.6% to $43.8 million, while sales of medical technologies climbed 13% to $35.7 million.. \n\n\n  Chief Executive Jim Clemmer said the company's strategic transformation is bearing fruit, as its medical technologies continue to gain share. He added the company will capitalize on momentum by continuing to invest across its medical technology portfolio. \n\n\n  Clemmer also said he intends to retire next year, prompting AngioDynamics' board to establish a new committee to conduct a search for the company's next CEO. \n\n\n  Shares rose 8.7%, to $14.38, in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 06:27 ET (11:27 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}